Immunic, Inc. · NASDAQ:IMUX

Immunic — Technical Presentation (October 2023)

34 slides from Immunic's technical presentation, Oct 10, 2023

  1. Slide 1: Positive Interim Data of Vidofludimus Calcium in Progressive Multiple Sclerosis

    Positive Interim Data of Vidofludimus Calcium in Progressive Multiple Sclerosis Phase 2 CALLIPER Trial October 10, 2023

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

  3. Slide 3: Disability Worsens Over Time in All Forms of MS

    Disability Worsens Over Time in All Forms of MS The Different Indications Have Different Paths and Drivers of the Disability Progression Relapsing Forms of MS (RMS) Progressive Forms of MS (PMS) RRMS Active SPMS Non-Active SPMS PPMS § Relapses and MRI lesions dominate § Fewer relapses and lesions wi

  4. Slide 4: Phase 2 CALLIPER Trial

    Phase 2 CALLIPER Trial Background Information

  5. Slide 5: CALLIPER: Ongoing Phase 2 Clinical Trial in Progressive Multiple Sclerosis (PMS)

    CALLIPER: Ongoing Phase 2 Clinical Trial in Progressive Multiple Sclerosis (PMS) Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial* Main Treatment Period (Blinded) Screening Period § Coordinating Investigator: Robert J. Fox, M.D., Cleveland Clinic Maximum 120 Weeks § 467 patien

  6. Slide 6: Patient Demographics and Baseline Characteristics

    Patient Demographics and Baseline Characteristics Total Study Population of 467 Enrolled Patients Progressive Disease Subtypes Baseline Characteristics Baseline Patient Characteristics Total (N=467) N=37 7.9% Age [years], median (min-max) 51.0 (21-65) N=152 Gender (n and % female) 302 (64.7 %) 32.5%

  7. Slide 7: Interim Analysis of the Phase 2 CALLIPER Trial

    Interim Analysis of the Phase 2 CALLIPER Trial Prospectively Planned Interim Biomarker Analysis § Interim analysis for biomarkers serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), when approximately half of the enrolled subjects (≈225 patients) have completed 24 weeks

  8. Slide 8: Neurofilament Light Chain (NfL)

    Neurofilament Light Chain (NfL) Background Information

  9. Slide 9: Neurofilaments Are Neuronal Proteins That Release Several Peptides Measurable in Blood

    Neurofilaments Are Neuronal Proteins That Release Several Peptides Measurable in Blood (Upon Neuronal Cell Death) Cross-Disease Neurologic Biomarker for Neurogenerative Diseases § Neurofilaments are highly specific neuronal proteins that, during neuronal injury, release several peptides into cerebro

  10. Slide 10: PPMS Patients Treated with Ocrelizumab That Achieved Lower Levels of NfL Had a Lower Risk

    PPMS Patients Treated with Ocrelizumab That Achieved Lower Levels of NfL Had a Lower Risk for Future Disability Ocrelizumab ORATORIO Study in PPMS as Historical Comparison § Blood NfL levels re-baselined at Week 48, an optimized cut-off was created between high (H) and low (L) NfL levels § Patients

  11. Slide 11: Historical Comparison: Ocrelizumab Reduced Blood NfL Levels in the ORATORIO Study

    Historical Comparison: Ocrelizumab, the Only Approved Drug for PPMS, Reduced Blood NfL Levels in the ORATORIO Study ORATORIO Showed a 12.4 % Delta for 24-Week Serum NfL Levels for Ocrelizumab Versus Placebo § Blood NfL levels (geometric mean and 95% CI, top) and relative change from baseline (% redu

  12. Slide 12: Neurofilament Light Chain (NfL)

    Neurofilament Light Chain (NfL) Interim Analysis of the Phase 2 CALLIPER Trial

  13. Slide 13: Improvements in Serum NfL for Vidofludimus Calcium Consistent Throughout PMS Population

    Improvements in Serum NfL for Vidofludimus Calcium Consistent Throughout the Overall PMS Population and All Subtypes Change to Week 24 as Compared to Placebo in % of Baseline Overall PMS Population PPMS n-aSPMS aSPMS 10% N=102 (IMU-838) N=32 (IMU-838) N=62 (IMU-838) N=8 (IMU-838) N=101 (Placebo) N=2

  14. Slide 14: NfL Reduction Compares Favorably with Other MS Therapies

    NfL Reduction Compares Favorably with Other MS Therapies CALLIPER Interim Data Compared to Select Historical Trials Vidofludimus Ocrelizumab Vidofludimus Siponimod Vidofludimus Siponimod Vidofludimus Ocrelizumab Evobrutinib PPMS PPMS n-aSPMS n-aSPMS aSPMS aSPMS RRMS RMS RRMS (CALLIPER) (ORATORIO) (C

  15. Slide 15: Improvements in Serum NfL in Patients With/Without Disease or MRI Activity

    Improvements in Serum NfL for Vidofludimus Calcium in Patients With/Without Disease or MRI Activity Change to Week 24 as Compared to Placebo in % of Baseline 10% Overall PMS Population aPMS n-aPMS aMRI n-aMRI N=102 (IMU-838) N=27 (IMU-838) N=75 (IMU-838) N=26 (IMU-838) N=76 (IMU-838) N=101 (Placebo)

  16. Slide 16: Vidofludimus Calcium Shows Lowering of NfL at Week 24 in Non-Active PMS

    Vidofludimus Calcium Shows Lowering of NfL at Week 24 in Patients with Non-Active PMS Disease (“Smoldering Disease”) First-in-Class Nurr1 Activator, Targeting Improvement of Physical Ability of MS Patients Nurr1 Activator DHODH Inhibitor § Protecting neurons § Selective anti-inflammatory from cell d

  17. Slide 17: Substantive Reduction of Serum NfL Levels Observed in CALLIPER Interim Analysis

    Substantive Reduction of Serum NfL Levels Observed in CALLIPER Interim Analysis – Promising Signal for Study Readout NfL levels reduced by 22.4% versus placebo in vidofludimus calcium treatment arm Reduction of NfL consistently shown across all subgroup analyses NfL effect observed in non-active SPM

  18. Slide 18: Glial Fibrillary Acidic Protein (GFAP)

    Glial Fibrillary Acidic Protein (GFAP) Interim Analysis of the Phase 2 CALLIPER Trial

  19. Slide 19: Biology of Glial Fibrillary Acidic Protein (GFAP)

    Biology of Glial Fibrillary Acidic Protein (GFAP) GFAP is a Non-Neuronal Biomarker Presumably Related to Diffuse Brain Disease § Astrocytes are the most numerous non-neuronal cells in the human central nervous system (CNS) - Provide cytoskeleton structure - Perform metabolic, structural, homeostatic

  20. Slide 20: Promising Early Signal for GFAP in the Overall PMS Population

    Promising Early Signal for GFAP in the Overall PMS Population Change in GFAP as Compared to Normalized Baseline Total Interim Analysis Population (24-Week Completer) 48-Week Completer Subpopulation N=102 (45 mg IMU-838), N=101 (Placebo) N=41 (45 mg IMU-838), N=38 (Placebo) Serum GFAP concentrations

  21. Slide 21: Promising Signal for GFAP Observed in CALLIPER Interim Analysis

    Promising Signal for GFAP Observed in CALLIPER Interim Analysis Although early, interim GFAP data showed a promising initial signal Progression of GFAP response is generally thought to evolve more slowly and with lower amplitude than NfL Company believes that a longer follow-up may further strengthe

  22. Slide 22: Positive Interim Biomarker Data of Vidofludimus Calcium in PMS

    Positive Interim Biomarker Data of Vidofludimus Calcium in Progressive Multiple Sclerosis (PMS) Biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential Vidofludimus calcium aim

  23. Slide 23: Vidofludimus Calcium in MS: Straightforward Path Towards Potential Regulatory Approval

    Vidofludimus Calcium in MS: Straightforward Path Towards Potential Regulatory Approval ENSURE CALLIPER ENSURE-1 ENSURE-2 NDA Interim Analysis Readout Readout Readout Submission Late 2024 April 2025 End of 2025 2026 2026 H2 H1 H2 H1 H2 H1 H2 H1 2024 2025 2026 Phase 3 ENSURE-1 Trial in RMS Phase 3 ENS

  24. Slide 24: Consistent and Differentiated Results to Date in Both RMS and PMS

    Consistent and Differentiated Results to Date in Both RMS and PMS Assembling the Basis for Potential Regulatory Approvals Full readout of phase 3 ENSURE program in RMS Full readout of phase 2 CALLIPER trial in PMS Interim, non-binding futility analysis of phase 3 ENSURE program in RMS Positive phase

  25. Slide 25: Q&A Session

    Q&A Session Interim Analysis of the Phase 2 CALLIPER Trial

  26. Slide 26: Thank You!

    Thank You! Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gräfelfing (Munich) USA Germany Jessica Breu Head of IR & Communications Immunic Australia Pty. Ltd. Phone: +49-89-2080477-09 Melbourne Email: [email protected] Australia Web: www.imux.com 26

  27. Slide 27: Backup

    Backup Interim Analysis of the Phase 2 CALLIPER Trial

  28. Slide 28: Key Challenge in All Forms of MS: Disability Worsening Over Time

    Key Challenge in All Forms of MS: Disability Worsening Over Time RRMS: Relapsing Forms of MS (RMS) Progressive Forms of MS (PMS) PPMS: § Dominated by focal § Patients worsen on disability inflammatory disease over time since diagnosis Disability Worsening (MRI lesions) and relapses despite no relaps

  29. Slide 29: Patient Demographics and Baseline Characteristics

    Patient Demographics and Baseline Characteristics Total Study Population of 467 Enrolled Patients Progressive Disease Subtypes Baseline Characteristics Baseline Patient Characteristics Total (N=467) N=37 Age [years], median (min-max) 51.0 (21-65) 7.9% Gender (n and % female) 302 (64.7 %) N=152 32.5%

  30. Slide 30: Overall PMS Population: Change in Serum NfL Compared to Normalized Baseline

    Overall PMS Population: Change in Serum NfL Compared to Normalized Baseline Total Interim Analysis Population (24-Week Completer) 48-Week Completer Subpopulation N=102 (45 mg IMU-838), N=101 (Placebo) N=41 (45 mg IMU-838), N=38 (Placebo) 2.705 1.60 Serum NfL concentrations (in ng/L) Serum NfL concen

  31. Slide 31: Overall PMS Population: Post-Hoc Statistical Analysis of Change in Serum NfL

    Overall PMS Population: Change in Serum NfL Post-Hoc Statistical Analysis of Change from Baseline to Week 24 Total Interim Analysis Population (24-Week Completer) N=102 (45 mg IMU-838), N=101 (Placebo) Nominal Change in NfL Post-Hoc Statistical Analysis: from BL to W24 Δ +2.705 ng/L (Placebo) The no

  32. Slide 32: Change in Serum NfL by PMS Disease Subtype

    Change in Serum NfL by PMS Disease Subtype Change from Baseline to Week 24 in % of Baseline PPMS n-aSPMS aSPMS 40% 35.6% 30% 20% 17.8% 10.8% 10% 0% -1.0% -10% -7.7% -9.3% -20% -30% N=32 (IMU-838) N=62 (IMU-838) N=8 (IMU-838) N=27 (Placebo) N=62 (Placebo) N=12 (Placebo) -40% 45 mg IMU-838 Placebo Sta

  33. Slide 33: Change in Serum NfL by Active Disease Status During Study

    Change in Serum NfL by Active Disease Status During Study Change from Baseline to Week 24 in % of Baseline, 45 mg of Vidofludimus Calcium aPMS n-aPMS 25% 20% 18.8% 15% 13.8% 10% 5% 0% -5% -2.6% -10% -15% -12.9% -20% N= 27 (IMU-838) N=75 (IMU-838) -25% N=35 (Placebo) N=66 (Placebo) 45 mg IMU-838 Plac

  34. Slide 34: Change in Serum NfL by MRI Activity During Study

    Change in Serum NfL by MRI Activity During Study Change from Baseline to Week 24 in % of Baseline, 45 mg of Vidofludimus Calcium aMRI n-aMRI 25% 21.1% 20% 15% 12.7% 10% 5% 0% -5% -3.0% -10% -15% -12.6% -20% N= 26 (IMU-838) N=76 (IMU-838) -25% N=32 (Placebo) N=69 (Placebo) 45 mg IMU-838 Placebo Activ

Immunic — Technical Presentation (October 2023) on 6ix